Empagliflozin Dosing and Clinical Benefits Guidelines

Standard Dosing and Administration

The American College of Cardiology recommends empagliflozin 10 mg daily as the standard starting dose for most patients with type 2 diabetes 1, 2

For patients with eGFR ≥20 ml/min/1.73 m², the standard 10 mg daily dose is recommended, according to Kidney International 3
For patients with eGFR <45 ml/min/1.73 m², empagliflozin is not recommended for glycemic control, though it may still be used for cardiovascular or renal benefits, as suggested by the American College of Cardiology 1, 2
For patients with eGFR <20 ml/min/1.73 m², empagliflozin should not be initiated, as stated in Kidney International 3
Once initiated, empagliflozin can be continued at lower levels of eGFR until dialysis for cardiovascular and kidney benefits, according to Kidney International and the American College of Cardiology 1, 3

In patients with heart failure with reduced ejection fraction (HFrEF), empagliflozin 10 mg daily is recommended regardless of diabetes status, as recommended by the American College of Cardiology 4
For patients with diabetic kidney disease and eGFR ≥20 ml/min/1.73 m², empagliflozin is recommended independent of A1C levels, according to Kidney International 3
No dose adjustment is required for patients with mild to moderate hepatic impairment, as stated by the American College of Cardiology 4

Discontinue empagliflozin at least 3 days before scheduled surgery to reduce risk of ketoacidosis, as recommended by the American College of Cardiology 1, 2
Monitor for genital mycotic infections, which occur more frequently with SGLT2 inhibitors, according to Kidney International 3
Consider reducing diuretic doses in patients taking concurrent diuretics due to potential volume depletion, as suggested by the American College of Cardiology 1, 2
Monitor for signs of ketoacidosis, especially during illness, reduced oral intake, or fluid losses, as recommended by the American College of Cardiology 1
Assess for urinary tract infections, which may occur more frequently with SGLT2 inhibitor therapy, according to the American College of Cardiology 1, 2

Empagliflozin provides cardiovascular benefits with a 26% reduction in the composite endpoint of cardiovascular death or hospitalization for heart failure, as reported by the American College of Cardiology 1
The medication offers renal protection by slowing eGFR decline in patients with diabetic kidney disease, according to Kidney International 3